CG Oncology, Inc. Common stock
HealthcareNASDAQ:CGON · NASDAQ Global Select
+$2.36 today
Vol 0.85M · Avg 1.20M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$161.0M -82.9% | -$88.0M -81.1% | -$48.6M -37.1% | -$35.4M -176.1% | -$12.8M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $1.4M +4415.6% | $32.0K +88.2% | $17.0K +13.3% | $15.0K +50.0% | $10.0K | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $26.7M +134.0% | $11.4M +646.2% | $1.5M +126.0% | $676.0K -39.2% | $1.1M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $2.3M -21.7% | $2.9M -15.5% | $3.4M -22.5% | $4.4M +325.7% | -$2.0M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$320.0K +53.6% | -$689.0K | $0 | $0 | $0 | $592.6M | $1.3B | $626.2M |
| Inventory | -$444.0K | $0 | $0 | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$1.6M -150.2% | $3.3M +62.8% | $2.0M +11277.8% | -$18.0K -103.1% | $578.0K | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $4.7M +1363.8% | $320.0K -77.6% | $1.4M -68.0% | $4.5M +275.1% | -$2.5M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$1.7M +65.1% | -$5.0M -143.9% | -$2.1M -503.9% | $509.0K +1596.7% | $30.0K | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$132.3M -68.1% | -$78.7M -72.3% | -$45.7M -53.3% | -$29.8M -118.3% | -$13.7M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$134.0K +42.7% | -$234.0K | $0 +100.0% | -$14.0K +85.6% | -$97.0K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | -$22.0M | $0 | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$1.1B -2.1% | -$1.0B -102.1% | -$517.6M -835.4% | -$55.3M | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $844.1M +13.2% | $745.4M +88.0% | $396.4M | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$245.8M +18.3% | -$300.8M -148.2% | -$121.2M -119.0% | -$55.4M -56963.9% | -$97.0K | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 +100.0% | -$365.0K +97.8% | -$16.3M | $0 -100.0% | $15.2M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $153.6M -75.6% | $629.5M | $0 -100.0% | $166.0K -32.2% | $245.0K | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 +100.0% | -$825.0K +38.4% | -$1.3M | $0 | $0 | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $153.6M -75.6% | $628.3M +622.2% | $87.0M -27.3% | $119.7M +674.9% | $15.4M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$224.6M -190.3% | $248.8M +411.5% | -$79.9M -331.3% | $34.5M +1937.5% | $1.7M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$132.5M -67.8% | -$78.9M -72.8% | -$45.7M -53.2% | -$29.8M -116.8% | -$13.8M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Legend Biotech Corporation
NASDAQ:LEGN
$6.71B
Centessa Pharmaceuticals plc
NASDAQ:CNTA
$6.14B
Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.47B
Travere Therapeutics, Inc.
NASDAQ:TVTX
$4.85B
Celcuity Inc.
NASDAQ:CELC
$4.33B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.12B
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
$2.66B
Disc Medicine, Inc.
NASDAQ:IRON
$2.60B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.40B
Ascentage Pharma Group International
NASDAQ:AAPG
$411.36M
SEC Filings
Recent regulatory filings
No filings found.
Does CGON generate free cash flow?
CG Oncology, Inc. Common stock (CGON) generated -$132,480,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does CGON produce?
Operating cash flow was -$132,346,000.00, before capital expenditures of $134,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.